Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global ADC Linker & Conjugation Technologies Markets to 2030 - Featuring Executive Insights from Stakeholders in Miracogen, NBE Therapeutics, Synaffix and EUCODIS Bioscience

      Research and Markets Logo

      News provided by

      Research and Markets

      Feb 18, 2020, 10:15 ET

      Share this article

      Share this article


      DUBLIN, Feb. 18, 2020 /PRNewswire/ -- The "Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

      This report features an extensive study of the current landscape and the likely future opportunities within the ADC linker and conjugation technologies market, over the next 10-12 years.

      One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for ADC linker and conjugation technologies. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2019-2030.

      The report also features the likely distribution of the current and forecasted opportunity across the:

      • [A] type of linker (cleavable, non-cleavable and both)
      • [B] type of conjugation (chemical, enzymatic and others)
      • [C] key technologies
      • [D] key geographical regions (North America, Europe and Asia Pacific/Rest of the World)

      With six approved drugs, namely POLIVY (2019), LUMOXITI (2018), BESPONSA (2017), MYLOTARG (2017, reapproval), KADCYLA (2013) and ADCETRIS (2011), and more than 200 in the pipeline (clinical/preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics.

      The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells/pathogens, consequently, addressing most of the concerns related to off target toxicities. In this context, the role of the linker molecule and the conjugation technology used is pivotal. In fact, conjugation chemistry has been shown to be directly related to the drug to antibody ratio (DAR) achieved, and thereby, governs the pharmacokinetic and pharmacodynamic properties of an ADC. Over time, a variety of other conjugated therapeutics have also been developed and are under evaluation.

      Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. Over time, the evolution of recombinant DNA technology and advances in conjugation techniques, have enabled researchers to significantly improve the bioconjugation process. In fact, next-generation conjugation technologies use artificially integrated lysine/cysteine residues in order to improve the DAR of the resulting conjugate.

      Additionally, there are multiple technologies that claim to offer site-specific conjugation. There are a number of other noteworthy developments in the conjugation technologies domain, which include a variety of competent platforms based on various ligation, disulfide rebridging and protein remodeling approaches. Further, linker technologies have also evolved substantially, and there is vast array of linkers, including cleavable and non-cleavable variants, which are designed to govern drug release mechanism of conjugated therapeutic molecules.

      It is worth highlighting that multiple licensing agreements/collaborations have been inked between drug developers and technology providers to advance the development of pipeline ADC candidates. Over the years, a number of start-ups/small companies, offering novel conjugation technologies, more potent cytotoxins/warheads and advanced linker chemistries, have been established to facilitate development of ADCs and other conjugated pharmaceuticals. We anticipate this niche and upcoming market to witness substantial growth over the coming years.

      In addition to other elements, the report includes:

      • An overview of the overall landscape of ADC linker and conjugation technologies, featuring an in-depth analysis of the technologies, based on a number of parameters, such as type of technology, generation of the technology (first, second and third), type of linker (cleavable, non-cleavable), type of conjugation (chemical, enzymatic and others), site specificity (specific and non-specific), DAR of the ADCs developed, patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of linker and conjugation technologies developers and analysis based on parameters, such as year of establishment, company size and geographical location.
      • Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
      • An analysis of the partnerships that have been established in the recent past, covering licensing agreements, product development and commercialization agreements, research and development agreements, product integration agreements, combination therapy development agreements, platform utilization agreements, and other relevant agreements.
      • A list of ADC therapeutic developers that are anticipated to partner with technology providers in future based on a detailed analysis of relevant parameters, such as availability of existing partners, availability of inhouse technology, company size (employee count), company's ADC pipeline strength, likely partners and development status of the ADC molecules.
      • A detailed competitiveness analysis of ADC linker and conjugation technologies, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as ADC generation, type of linker, DAR of the ADCs developed using the technology, availability of patent protection, number of deals signed for a particular technology (2016-2019), and popularity of the technology (in terms of the number of ADCs developed using the technology).
      • An in-depth analysis of the various patents that have been filed/granted related to linker/conjugation technologies till August 2019, taking into consideration parameters, such as patent type, publication year, issuing authority/patent offices involved, CPC symbol, emerging focus areas and leading industry/academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

      In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

      Key Topics Covered

      1. PREFACE
      1.1. Scope of the Report
      1.2. Research Methodology
      1.3. Chapter Outlines

      2. EXECUTIVE SUMMARY

      3. INTRODUCTION
      3.1. Chapter Overview
      3.2. Antibody-based Therapeutics
      3.3 Antibody Drug Conjugates (ADCs)
      3.3.1 Components of ADCs
      3.3.1.1 Antibody
      3.3.1.2 Cytotoxin
      3.3.1.3 Linker
      3.4. Advantages of ADCs over Traditional Pharmacological Interventions
      3.5. ADC Linker Technologies
      3.5.1. Non-cleavable Linkers
      3.5.2. Cleavable Linkers
      3.6. ADC Conjugation Technologies
      3.6.1. Chemical Conjugation
      3.6.2. Enzymatic Conjugation
      3.7. Future Perspectives

      4. CURRENT MARKET LANDSCAPE
      4.1. Chapter Overview
      4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
      4.2.1. Analysis by Type of Technology
      4.2.2. Analysis by ADC Generation
      4.2.3. Analysis by Type of Linker
      4.2.4. Analysis by Type of Conjugation
      4.2.5. Analysis by Site Specificity
      4.2.6. Analysis by Drug to Antibody Ratio
      4.2.7. Analysis by Patent Availability
      4.2.8. Analysis by Licensing Activity
      4.3. ADC Linker and Conjugation Technologies: Developer Landscape
      4.3.1 Analysis by Year of Establishment
      4.3.2 Analysis by Company Size
      4.3.3 Analysis by Geographical Location
      4.3.4 Leading ADC Developers: Analysis by Number of Technologies
      4.3.5 Grid Representation: Analysis by ADC Generation, Type of Linker, Company Size, and Geographical Location
      4.3.6 World Map Representation: Analysis by Geography
      4.4 ADC Linker and Conjugation Technologies: Service Providers

      5. COMPANY PROFILES
      5.1 Chapter Overview
      5.2 Key Players in North America
      5.2.1 Ambrx
      5.2.1.1 Company Overview
      5.2.1.2 Technology Overview
      5.2.1.3 Recent Developments and Future Outlook
      5.2.2 Catalent Biologics
      5.2.3 Immunomedics
      5.2.4 Mersana Therapeutics
      5.2.5 Seattle Genetics
      5.2.6 Sutro Biopharma
      5.3 Key Players in Europe and Asia
      5.3.1 Iksuda Therapeutics
      5.3.2 LegoChem Biosciences
      5.3.3 LinXis
      5.3.4 NBE Therapeutics

      6. PARTNERSHIPS AND COLLABORATIONS
      6.1 Chapter Overview
      6.2 Partnership Models
      6.3 List of Partnerships and Collaborations
      6.3.1 Analysis by Year of Partnership
      6.3.2 Analysis by Type of Partnership
      6.3.3 Analysis by Type of Linker
      6.3.4 Analysis by Type of Conjugation
      6.3.5 Analysis by Year of Partnership and Type of Partner
      6.3.6 Analysis by Type of Partnership and Type of Partner
      6.3.7 Most Active Players: Analysis by Number of Partnerships
      6.3.8 Most Popular Technologies: Analysis by Number of Partnerships
      6.3.9 Regional Analysis
      6.3.10 Intercontinental and Intracontinental Agreements

      7. LIKELY PARTNERS ANALYSIS
      7.1 Chapter Overview
      7.2 Scope and Methodology
      7.3 ADC Linker and Conjugation Technologies: Potential Strategic Partners in North America
      7.3.1 Most Likely Partners
      7.3.2 Likely Partners
      7.3.3 Less Likely Partners
      7.4 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Europe
      7.5 ADC Linker and Conjugation Technologies: Potential Strategic Partners in Asia-Pacific

      8. TECHNOLOGY COMPETITIVENESS ANALYSIS
      8.1 Chapter Overview
      8.2 Methodology
      8.3 Assumptions and Key Parameters
      8.4 Technology Competitiveness Analysis
      8.4.1 Technologies Developed by Companies based in North America
      8.4.2 Technologies Developed by Companies based in Europe
      8.4.3 Technologies Developed by Companies based in Asia Pacific / RoW

      9. PATENT ANALYSIS
      9.1 Chapter Overview
      9.2 Scope and Methodology
      9.3 ADC Linker and Conjugation Technologies: Patent Portfolio
      9.3.1 Analysis by Publication Year
      9.3.2 Analysis by Issuing Authority / Patent Offices Involved
      9.3.3 Analysis by CPC Symbols
      9.3.4 Emerging Focus Areas
      9.3.5 Analysis by Type of Company / Organization
      9.3.6 Leading Assignees: Analysis by Number of Patents
      9.4 ADC Linker and Conjugation Technologies: Patent Benchmarking Analysis
      9.4.1 Analysis by Patent Characteristics
      9.5 ADC Linker and Conjugation Technologies: Patent Valuation Analysis

      10. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
      10.1 Chapter Overview
      10.2 First Generation ADC Technologies
      10.3 Second Generation ADC Technologies
      10.3.1 Cysteine and Selenocysteine Engineering
      10.3.2 Unnatural Amino Acid Engineering
      10.3.3 Amino-Terminal Serine Engineering
      10.4 Third Generation ADC Technologies
      10.4.1 Enzyme-Assisted Ligation Approaches
      10.4.2 Glycan Remodeling Approaches
      10.4.3 Ligation at Fab Nucleotide-Binding Site
      10.4.4 Cysteine Rebridging
      10.4.5 Avoiding or Limiting Retro-Michael Drug Deconjugation
      10.5 Evolutionary Analysis

      11. MARKET SIZING AND FORECAST
      11.1 Chapter Overview
      11.2 Forecast Methodology and Key Assumptions
      11.3 Global ADC Linker and Conjugation Technologies Market, 2019-2030
      11.4 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2019-2030
      11.5 Global ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2019-2030
      11.6 Global ADC Linker and Conjugation Technologies Market: Share of Key Technologies, 2019-2030
      11.7 Global ADC Linker and Conjugation Technologies Market: Distribution by Region, 2019-2030
      11.7.1 ADC Linker and Conjugation Technologies Market in North America, 2019-2030
      11.7.2 ADC Linker and Conjugation Technologies Market in Europe, 2019-2030
      11.7.3 ADC Linker and Conjugation Technologies Market in Asia Pacific, 2019-2030

      12. EXECUTIVE INSIGHTS
      12.1 Chapter Overview
      12.2 Miracogen
      12.2.1 Company Snapshot
      12.2.2 Interview Transcript: Mary Hu, Chief Executive Officer
      12.3 NBE Therapeutics
      12.4 Synaffix
      12.5 EUCODIS Bioscience

      13. CONCLUDING REMARKS

      14. APPENDIX 1: TABULATED DATA

      15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

      • 3P Biopharmaceuticals
      • 3SBio
      • AbbVie
      • AbGenomics
      • ABL Bio
      • Abnova
      • Abzena
      • ACES Pharma
      • ADC Biotechnology
      • ADC Therapeutics
      • Advanced Proteome Therapeutics
      • Affinity Life Sciences
      • AGC Biologics
      • Agensys
      • Ajinomoto
      • Ajinomoto Bio-Pharma Services
      • Albumedix
      • Alexion Pharmaceuticals
      • Allergan
      • Alpha Cancer Technologies
      • Alta Partners
      • Alteogen
      • Ambrx
      • Amgen
      • Angiex
      • Antikor Biopharma
      • Araris Biotech
      • Asana BioSciences
      • Astellas Pharma
      • AstraZeneca
      • Avacta Life Sciences
      • Bayer
      • BeiGene
      • BioAtla
      • BioCapital
      • Biogen
      • BioLegend
      • BioMed Valley Discoveries
      • BioOutsource
      • Bio-Rad Laboratories
      • Bio-Synthesis
      • Biotechnique
      • Biotest
      • Bio-Thera Solutions
      • BlinkBio
      • Bliss Biopharmaceutical
      • BOC Sciences
      • Boehringer Ingelheim
      • Boster Biological Technology
      • Bristol-Myers Squibb
      • BSP Pharmaceuticals
      • Cancer Research UK
      • Capra Science Antibodies
      • CARBOGEN AMCIS
      • Cascadian Therapeutics
      • Catalent Biologics
      • Celgene
      • CellMosaic
      • Cell Signalling Technology
      • Cellerant Therapeutics
      • Celltrion
      • Centrose
      • Cerbios-Pharma
      • Chugai Pharmaceutical
      • Cisbio
      • Clovis Oncology
      • Concortis Biotherapeutics
      • Corixa
      • Creative Biolabs
      • Creative Diagonostics
      • Creative peptides
      • CSPC Pharmaceutical Group
      • CureMeta
      • Cytogen
      • CytomX Therapeutics
      • Daiichi Sankyo
      • Dalton Pharma Services
      • Debiopharm Group
      • Dyax
      • Eisai
      • Elan Pharmaceuticals
      • Eli Lilly
      • Elusys Therapeutics
      • EMD Serono
      • Envigo
      • Esperance Pharmaceuticals
      • EUCODIS Bioscience
      • Eventide Asset Management
      • Everest Biotech
      • Everest Medicines
      • Exelixis
      • Expedeon
      • Femtogenix
      • Fleet Bioprocessing
      • Formation Biologics
      • Formosa Laboratories
      • Fortis Therapeutics
      • Fosun Pharma
      • GamaMabs Pharma
      • Genentech
      • Genmab
      • Genovis
      • GenScript
      • Genzyme
      • GlaxoSmithKline
      • Glycotope
      • Glythera
      • Goodwin Biotechnology
      • GT Biopharma
      • Hangzhou DAC Biotech
      • Heidelberg Pharma
      • Hengrui Medicine
      • Human Genome Sciences
      • iBioSource
      • Iconic Therapeutics
      • Iksuda Therapeutics
      • ImClone Systems
      • ImmunoBiochem
      • ImmunoGen
      • Immunomedics
      • Innate Pharma
      • Innovate UK
      • IntoCell
      • IONTAS
      • iProgen Biotech
      • Iterum Therapeutics
      • Janssen Biotech
      • Johnson & Johnson
      • Johnson Matthey
      • Kairos Therapeutics
      • KLUS Pharma
      • Kyowa Hakko Kirin
      • LakePharma
      • LegoChem Bioscienses
      • Leinco Technologies
      • Leukemia & Lymphoma Society
      • Levena Biopharma
      • Life Technologies
      • Light Chain Bioscience
      • Lilly Ventures
      • LinXis
      • MabPlex
      • MabSpace Biosciences
      • MabVax Therapeutics
      • MacroGenics
      • Magenta Therapeutics
      • Maine Biotechnology
      • MediaPharma
      • MedImmune
      • Meditope Biosciences
      • MedKoo Biosciences
      • Memorial Sloan Kettering Cancer Center
      • Menarini Group
      • Merck
      • Mersana Therapeutics
      • Millennium Pharmaceuticals
      • Mitsubishi Tanabe Pharma
      • MorphoSys
      • Morphotek
      • MuseChem
      • NanoValent Pharmaceuticals
      • National Research Council of Canada
      • NBE-Therapeutics
      • NeoRx
      • Nexthera Capital
      • Nordic Nanovector
      • Noria Pharmaceuticals
      • Novartis
      • NovaTeinBio Novimmune
      • NovoCodex Biopharmaceuticals
      • Novozymes
      • OBI Pharma
      • OcellO
      • OGD2 Pharma
      • Oncolinx
      • Oncomatryx Biopharma
      • Oncotec Pharma Produktion
      • Organon Teknika
      • OriGene Technologies
      • Oxford BioTherapeutics
      • Palatin Technologies
      • Pfizer
      • Pharmaron
      • Philochem
      • Pierre Fabre
      • Piramal Pharma Solutions
      • ProBioGen
      • Progenics Pharmaceuticals
      • ProteoGenix
      • Puma Biotechnology
      • Rakuten Medical
      • Recepta Biopharma
      • Redwood Bioscience
      • Regeneron Pharmaceuticals
      • RemeGen
      • Roche
      • Rockland Immunochemicals
      • SafeBridge Consultants
      • Samsung Medical Center
      • Sanofi
      • Seattle Genetics
      • Seramun Diagnostica
      • Servier
      • Sesen Bio
      • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
      • Shanghai Jiaolian Medicine Research and Development
      • Shanghai Miracogen
      • Shenogen Pharma
      • Shire
      • Siamab Therapeutics
      • Skyline Ventures
      • Sorrento Therapeutics
      • SOTIO
      • SouthernBiotech
      • Sun Pharmaceutical Industries
      • Sunomix Biosciences
      • Surveyor Capital
      • Sutro Biopharma
      • SV Health Investors
      • Swedish Orphan Biovitrum (Sobi)
      • Synaffix
      • Syngene International
      • Synthon
      • TaiMed Biologics
      • Takeda Pharmaceutical
      • TBD-Biodiscovery
      • Teresi Pharmaceuticals
      • Teva Pharmaceutical
      • The Johns Hopkins University School of Medicine
      • The University of Texas MD Anderson Cancer Center
      • Theratechnologies
      • Thermo Fisher Scientific
      • ThioLogics
      • TOT BIOPHARM
      • Triphase Accelerator
      • Tsuchikama Laboratory
      • UCB
      • Ultragenyx Pharmaceutical
      • United Therapeutics
      • UW Carbone Cancer Center
      • Vaccinex
      • Valeant Pharmaceuticals
      • VelosBio
      • Vida Ventures
      • Visterra
      • WuXi Biologics
      • Wyeth
      • Xintela
      • Yale Cancer Center
      • Y-Biologics
      • Zhejiang Hisun Pharmaceutical
      • Zymeworks

      For more information about this report visit https://www.researchandmarkets.com/r/l6ez8g

      Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

      Media Contact:


      Research and Markets
      Laura Wood, Senior Manager
      [email protected]   

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.